一种抗p-Tau181蛋白单克隆抗体及其制备方法和应用
By developing an antibody targeting the p-Tau181 protein, the shortcomings of existing antibodies in terms of specificity and sensitivity have been overcome, achieving highly specific recognition of the p-Tau181 protein and improving the accuracy of Alzheimer's disease diagnosis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI BIOGERM MEDICAL TECH CO LTD
- Filing Date
- 2024-12-02
- Publication Date
- 2026-07-17
AI Technical Summary
Existing antibodies lack specificity and sensitivity when recognizing p-Tau181 protein, which may lead to false positive and false negative results, and cannot effectively rule out cross-reactions with non-phosphorylated tau protein or other phosphorylation sites.
An antibody targeting the p-Tau181 protein was developed, containing a complementary determinant region (CDR) of specific heavy and light chain variable regions, which can bind to the p-Tau181 protein with high affinity, and the preparation method ensures that it does not recognize other phosphorylated forms of the Tau protein.
It achieves highly specific recognition and binding of p-Tau181 protein, reduces false positive and false negative results, and improves the accuracy of AD diagnosis.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3